Anti-TGFβ3 therapy resulted in the greatest delay in tumor growth (62.3% reduction in tumor size compared to control), followed by anti-TGFβ1 therapy (49.68%) and pan-TGFβ blockade (37.44%) calculated 24 days post tumor implantation (Fig. 3b, c). The gene discussed is TGFB3; the disease is neoplasm.